JenaValve Technology has closed $100 million series C financing led by Bain Capital Life Sciences.

Other investors in the round included newcomers Pictet Alternative Advisors SA, Qatar Investment Authority, Innovatus Capital Partners, and Peijia Medical, as well as existing investors Andera Partners, Valiance Advisors, Gimv, Cormorant Asset Management, RMM, and Venture Incubator.

The funds will be used to complete its investigational device exemption premarket approval study for Trilogy Heart Valve System, a treatment for high surgical risk patients with symptomatic, severe aortic regurgitation. JenaValve will also use the proceeds to bolster its real-world data development initiatives in Europe and expand its worldwide manufacturing capabilities.

This financing will provide sufficient capital for clinical trial and commercial launch in the US, and enhance sales in Europe, according to John Kilcoyne, CEO at JenaValve.